D. Azarnoff

发表

Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens

J. Reddy, C. Hignite, D. Azarnoff, 1980, Nature.

Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver.

J. Reddy, S. Sell, M. Rao, 1979, Cancer research.

NAFENOPIN-INDUCED HEPATIC MICROBODY (PEROXISOME) PROLIFERATION AND CATALASE SYNTHESIS IN RATS AND MICE

D. Azarnoff, J. Reddy, D. Svoboda, 1974, The Journal of cell biology.

Pharmacokinetics of methotrexate

D. Azarnoff, Suk Han Wan, D. Huffman, 1974, Clinical pharmacology and therapeutics.

Effect of cholesterol synthesis inhibition in normocholesteremic young men.

D. Azarnoff, G. L. Curran, R. Bolinger, 1959, The Journal of clinical investigation.

Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse.

J. Reddy, D. Azarnoff, D. Moody, 1977, Archives internationales de pharmacodynamie et de therapie.

Drug Protein Binding and the Nephrotic Syndrome

R. Gugler, D. Azarnoff, 1976, Clinical pharmacokinetics.

Diphenylhydantoin potency and plasma protein binding.

D. Azarnoff, D. Shoeman, 1975, The Journal of pharmacology and experimental therapeutics.

Individualization of treatment of hyperlipoproteinemic disorders.

D. Azarnoff, 1974, The Medical clinics of North America.

Colestipol and clofibrate in hypercholesterolemia

R. Kauffman, D. Azarnoff, C. Dujovne, 1974, Clinical pharmacology and therapeutics.

Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug.

D. Azarnoff, D. Svoboda, 1979, Cancer research.

Pharmacokinetic Investigations in Elderly Patients Clinical and Ethical Considerations

D. Abernethy, D. Azarnoff, Daniel L. Azarnoff, 1990, Clinical pharmacokinetics.

Cardiac Function in Healthy Men

K. Hassanein, D. Azarnoff, D. Huffman, 2005 .

Phenytoin: Pharmacokinetics and bioavailability

R. Gugler, D. Azarnoff, C. Manion, 1976, Clinical pharmacology and therapeutics.

Quality of Extemporaneously Compounded Nitroglycerin Ointment

D. Azarnoff, D. Karlin, J. Lee, 2007, Diseases of the colon and rectum.

Cadmium-induced Leydig cell tumors of rat testis: morphologic and cytochemical study.

R. Dawar, D. Azarnoff, D. Svoboda, 1973, Journal of the National Cancer Institute.

Metabolic disposition of antipyrine in patients with lung cancer.

C. Hignite, C. Tschanz, D. Azarnoff, 1977, Cancer research.

Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH

D. Azarnoff, S. Matin, S. H. Wan, 1978, Clinical pharmacology and therapeutics.

RESPONSE OF HEPATIC MICROBODIES TO A HYPOLIPIDEMIC AGENT, ETHYL CHLOROPHENOXYISOBUTYRATE (CPIB)

D. Azarnoff, D. Svoboda, 1966, The Journal of cell biology.

MICROBODIES IN EXPERIMENTALLY ALTERED CELLS

D. Azarnoff, D. Svoboda, J. Reddy, 1969, The Journal of cell biology.

Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.

D. Azarnoff, D. Svoboda, J. Reddy, 1973, Biochemical and biophysical research communications.

1-methyl-4piperidyl-bis (P-chlorophenoxy) acetate: a new hypolipidemic peroxisome proliferator.

D. Azarnoff, D. Moody, T. P. Krishnakantha, 1975, Research communications in chemical pathology and pharmacology.

Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643.

C. Sirtori, D. Azarnoff, J. Reddy, 1978, Archives internationales de pharmacodynamie et de therapie.

Hepatic Catalase Is Not Essential for the Hypolipidemic Action of Peroxisome Proliferators 1

M. Rao, D. Azarnoff, D. Moody, 1977, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Di-(2-ethylhexyl)phthalate: an industrial plasticizer induces hypolipidemia and enhances hepatic catalase and carnitine acetyltransferase activities in rat and mice.

M. Rao, D. Azarnoff, D. Moody, 1976, Life sciences.

Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism.

C. Sirtori, D. Azarnoff, P. Bolme, 1972, The New England journal of medicine.

THE ALTERATION OF PLASMA PROTEINS IN UREMIA AS REFLECTED IN THE ABILITY TO BIND DIPHENYLHYDANTOIN

D. Azarnoff, D. Shoeman, D. M. Benjamin, 1973, Annals of the New York Academy of Sciences.

Insecticides: Effect on drug metabolism

D. Azarnoff, 1977, Clinical pharmacology and therapeutics.

The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.

D. Azarnoff, D. Shoeman, 1972, Pharmacology.

Glucuronic acid conjugates of clofibrate: four isomeric structures.

C. Hignite, C. Tschanz, D. Azarnoff, 1981, Life sciences.

Long‐Term Effects of Clofibrate (Atromid‐S) on Serum Lipids in Man

D. R. Tucker, D. Hunninghake, D. Azarnoff, 1969, Circulation.

HYPOLIPIDEMIC HEPATIC PEROXISOME PROLIFERATORS FORM A NOVEL CLASS OF CHEMICAL CARCINOGENS

C. Hignite, D. Azarnoff, J. Reddy, 1980 .

Effect of environmental factors on drug metabolism: Decreased plasma half‐life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides

D. Azarnoff, F. Sjöqvist, Birgitta Kolmodin, 1969, Clinical pharmacology and therapeutics.

Diphenylhydantoin: Correlation between protein binding and albumin concentration

R. Gugler, D. Azarnoff, D. Shoeman, 1975, Klinische Wochenschrift.

SITE OF VANADIUM INHIBITION OF CHOLESTEROL BIOSYNTHESIS

D. Azarnoff, G. L. Curran, 1957 .

Separation and quantitative analysis of furosemide and 4-chloro-5-sulfamoylanthranilic adid (CSA) by high pressure liquid chromatography.

D. Azarnoff, D. Shoeman, M. MacDougall, 1975, Research communications in chemical pathology and pharmacology.

The effect of spironolactone on plasma levels and excretion of testosterone and oestrogens in the urine in males. (A preliminary report).

P. Pentikäinen, D. Azarnoff, D. Huffman, 1974, The Journal of international medical research.

Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin‐releasing factor in humans

S. Shafer, M. Angst, J. B. Dyck, 1998, Clinical pharmacology and therapeutics.

Effect of portacaval shunt on the disposition of drugs with and without first-pass effect.

R. Gugler, D. Azarnoff, P. Lain, 1975, The Journal of pharmacology and experimental therapeutics.

Drug Interactions: The Potential for Adverse Effects

D. Azarnoff, 1972 .

Transdermal Absorption: A Unique Opportunity for Drug Delivery

D. Azarnoff, A. Karim, H. Lambert, 1984 .

Hyperinsulinemia secondary to chronic administration of mazindol and d‐amphetamine

C. Sirtori, D. Azarnoff, A. Hurwitz, 1971, The American journal of the medical sciences.

DRUG INHIBITION OF CATECHOLAMINE‐INDUCED METABOLIC EFFECTS IN HUMANS *

D. Azarnoff, D. Waxman, D. Hunninghake, 1967, Annals of the New York Academy of Sciences.

Induction of Salicyluric Acid Formation in Rheumatoid Arthritis Patients Treated with Salicylates

R. Day, D. Shen, R. O. Day, 1983, Clinical pharmacokinetics.

Clinical Pharmacokinetics of Methotrexate

D. Shen, D. Azarnoff, 1978, Clinical pharmacokinetics.

Dissociation of the metabolic and cardiovascular effects of the beta-adrenergic blocker practolol1

C. Sirtori, D. Azarnoff, D. Shoeman, 1972 .

A comparative study of drug metabolism in the isolated perfused liver and in vivo in rats.

S. Orrenius, D. Azarnoff, B. Alexanderson, 1970, European journal of pharmacology.

Treatment of angina pectoris with chromonar hydrochloride

M. Dunn, D. Azarnoff, M. Dunn, 1968, Clinical pharmacology and therapeutics.

Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype

D. Shen, D. Azarnoff, J. Hosler, 1980, Journal of Pharmacokinetics and Biopharmaceutics.

Clinical complications of corticosteroid therapy. A selected review.

D. Azarnoff, C. Dujovne, Carlos A. Dujoune, 1973, The Medical clinics of North America.

Identification of methotrexate and folic acid analogs by mass spectrometry.

C. Hignite, D. Azarnoff, 1978, Biomedical mass spectrometry.

Topical application of lindane cream (Kwell) and antipyrine metabolism.

C. Hignite, C. Tschanz, D. Azarnoff, 1980, The Journal of investigative dermatology.

SEPARATION OF NUCLEAR SATURATED FROM UNSATURATED STEROLS.

D. R. Tucker, D. Azarnoff, 1963, Biochimica et biophysica acta.

Drugs and drug metabolites as environmental contaminants: chlorophenoxyisobutyrate and salicyclic acid in sewage water effluent.

C. Hignite, D. Azarnoff, D L Azarnoff, 1977, Life sciences.

Inhibition of cholesterol biosynthesis in man.

D. Azarnoff, G. L. Curran, 1958, A.M.A. archives of internal medicine.

Pharmacokinetics of drugs in patients with the nephrotic syndrome.

R. Gugler, D. Azarnoff, D. Shoeman, 1975, The Journal of clinical investigation.

Drugs as etiologic factors in the Stevens-Johnson syndrome.

L. Lasagna, D. Azarnoff, E. Hvidberg, 1968, The American journal of medicine.

Placental transfer of penicillin G during constant-rate infusion in the goat.

R. Kauffman, D. Azarnoff, B. Boulos, 1973, American journal of obstetrics and gynecology.

Effect of noradrenaline on the action of nicotine and tyramine on isolated atria.

D. Azarnoff, J. Burn, 1961, British journal of pharmacology and chemotherapy.

In vitro inhibition of rat liver cholest-5en-3β-ol (cholesterol) biosynthesis by non-mercurial sulfhydryl reagents

D. Abernethy, C. Hignite, D. Azarnoff, 1976, Steroids.

Placental Transfer and Fetal Urinary Excretion of Gentamicin during Constant Rate Maternal Infusion

R. Kauffman, John A. Morris, D. Azarnoff, 1975, Pediatric Research.

Peroxisome-associated enzymes and serum lipids in tumour-bearing rats treated with peroxisome-proliferating agents.

D. Azarnoff, D. Moody, J. Reddy, 1984, Biochemical pharmacology.

Effect of in vivo elevation of free fatty acids on protein binding of drugs.

R. Gugler, D. Azarnoff, D. Shoeman, 1974, Pharmacology.

Plasma protein binding of tricyclic anti-depressants in man.

D. Azarnoff, F. Sjöqvist, O. Borgå, 1969, Biochemical pharmacology.

MICROBODIES IN EXPERIMENTALLY ALTERED CELLS

M. Chiga, D. Azarnoff, D. Svoboda, 1970, The Journal of cell biology.

Gynecomastia induced in normal males by spironolactone

C. Hignite, D. Azarnoff, J. Kampmann, 1978, Clinical pharmacology and therapeutics.

High-pressure liquid chromatographic assay of theophylline in biological fluids.

D. Azarnoff, D. Shoeman, C. Manion, 1974, Journal of chromatography.

Effects of selected hypolipidemic drugs on cell ultrastructure.

D. Azarnoff, D. Svoboda, 1971, Federation proceedings.

Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets.

P. Pentikäinen, D. Azarnoff, S. H. Wan, 1974, Journal of pharmaceutical sciences.

Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans.

B. Hoogstraten, D. Azarnoff, W. Larsen, 1974, Cancer research.

The effect of spironolactone on antipyrine metabolism in man.

P. Pentikäinen, D. Azarnoff, D. Shoeman, 1973, Pharmacology.

Species Differences in Cholesterol Biosynthesis by Arterial Tissue.∗

D. Azarnoff, 1958, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

The Effect of Concurrent Oral Administration of Propranolol and Disopyramide on Cardiac Function in Healthy Men

D. Shen, D. Azarnoff, K. Hassanein, 1980, Circulation.

The effect of non-linear disposition kinetics on the systemic availability of disopyramide

D. Shen, D. Azarnoff, J. Cunningham, 1978 .

Clinical pharmacokinetics of disopyramide

D. Azarnoff, A. Karim, C. Nissen, 1982, Journal of Pharmacokinetics and Biopharmaceutics.

Absorption and excretion of clindamycin‐2‐phosphate in children after intramuscular injection

R. Kauffman, D. Azarnoff, S. H. Wan, 1972, Clinical pharmacology and therapeutics.

CLINICAL PRINCIPLES OF DRUG INTERACTIONS IN THE ADULT PATIENT *

D. Azarnoff, A. Hurwitz, Aryeh Hurwitz†, 1976, Annals of the New York Academy of Sciences.

Bioavailability of digoxin-hydroquinone complex: a new oral digoxin formulation.

D. Shen, F. Bochner, D. Azarnoff, 1977, Journal of pharmaceutical sciences.

Mitochondrial cavitation and hypertrophy in rat adrenal cortex due to aminoglutethimide.

D. Azarnoff, D. Svoboda, A. Racela, 1969, Laboratory investigation; a journal of technical methods and pathology.

MICROBODIES IN EXPERIMENTALLY ALTERED CELLS

D. Azarnoff, D. Svoboda, J. Reddy, 1969, The Journal of cell biology.

Computer-controlled Infusion of Intravenous Dexmedetomidine Hydrochloride in Adult Human Volunteers

M. Maze, C. Haack, L. Vuorilehto, 1993, Anesthesiology.

Quantitation of lidocaine and its deethylated metabolites in plasma and urine by gas chromatography-mass fragmentography.

C. Hignite, C. Tschanz, D. Azarnoff, 1978, Journal of chromatography.

Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker

D. Azarnoff, S. Carruthers, P. Pentikainen, 1979, Clinical pharmacology and therapeutics.

Quantitation of N-demethylantipyrine in biological samples and isolation and characterization of its glucuronic acid conjugate.

C. Hignite, C. Tschanz, D. Azarnoff, 1978, Drug metabolism and disposition: the biological fate of chemicals.

Physiologic factors in selecting human volunteers for drug studies

D. Azarnoff, 1972, Clinical pharmacology and therapeutics.

Drug interactions with warfarin.

D. Azarnoff, D. Hunninghake, 1968, Archives of internal medicine.

STUDIES WITH ETHYL CHLOROPHENOXYISOBUTYRATE (CLOFIBRATE).

D. R. Tucker, G. Barr, D. Azarnoff, 1965, Metabolism: clinical and experimental.

Long-Term Effects ofClofibrate (Atromid-S) on SerumLipids inMan

D. Azarnoff, 1969 .

Clofibrate effect on catecholamine-induced metabolic changes in humans.

D. Azarnoff, D. Hunninghake, 1968, Metabolism: clinical and experimental.

The effect of hypocholesterolemic drugs on adrenal corticosteroid secretion.

D. Azarnoff, D. Huffman, 1967, Steroids.

Micromethod for the determination of serum lipids.

D. Azarnoff, 1962, The Journal of laboratory and clinical medicine.

One‐year trials with halofenate, clofibrate, and placebo

D. Azarnoff, C. Dujovne, P. Pentikainen, 1976, Clinical pharmacology and therapeutics.

Clinical evaluation of MK-185: A new hypolipidemic drug

C. Sirtori, D. Azarnoff, A. Hurwitz, 1972, Lipids.

Effect of drugs which alter microsomal drug-metabolizing enzyme activity on rat hepatic cholesterol biosynthesis.

D. Abernethy, D. Azarnoff, 1977, Biochemical pharmacology.

Association between clinical cardiac status, laboratory parameters, and digoxin usage.

P. Pentikäinen, D. Azarnoff, J. Crow, 1976, American heart journal.

The Effects of Total Body Roentgen Irradiation On The Endocrine Glands and Other Organs of the Rat

D. Azarnoff, P. G. Roofe, 1952 .

Effect of route of administration and effusions on methotrexate pharmacokinetics.

B. Hoogstraten, D. Azarnoff, S. H. Wan, 1974, Cancer research.

Pharmacokinetics of methotrexate

B. Hoogstraten, D. Azarnoff, S. H. Wan, 1973, Clinical pharmacology and therapeutics.

Use of pharmacokinetic principles in therapy.

D. Azarnoff, 1973, The New England journal of medicine.

Incorporation of acetate-1-C14 into cholesterol by human intracranial tumors in vitro.

D. Azarnoff, W. Williamson, G. L. Curran, 1958, Journal of the National Cancer Institute.

Kinetics of R and S warfarin enantiomers

C. Hignite, C. Tschanz, J. Uetrecht, 1980 .

A specific site of vanadium inhibition of cholesterol biosynthesis

D. Azarnoff, G. L. Curran, F. E. Brock, 1961 .

Intersubject variation in absorption of digoxin in normal volunteers.

D. Azarnoff, D. Huffman, C. Manion, 1975, Journal of pharmaceutical sciences.

Drug interactions: Clinical significance

D. Azarnoff, 1974, Clinical pharmacology and therapeutics.

Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man.

D. Azarnoff, D. Shoeman, D. Huffman, 1974, Biochemical pharmacology.

Metabolic Dispositionof Antipyrinein Patients with Lung Cancer1

C. Hignite, C. Tschanz, D. Azarnoff, 1977 .

Absorption of orally given digoxin preparations.

D. Azarnoff, D. Huffman, 1972, JAMA.

Plasma Levels and Excretion of Estrogens in Urine in Chronic Liver Disease

P. Pentikäinen, D. Azarnoff, C. Dujovne, 1975 .

Correlation between plasma diphenhydramine level and sedative and antihistamine effects.

C. Hignite, D. Azarnoff, S. Carruthers, 1979, Clinical pharmacology and therapeutics.

Metabolic responses to plasma concentrations of theophylline

D. Azarnoff, W. Cathcart-Rake, J. Kyner, 1979, Clinical pharmacology and therapeutics.

Correlation between plasma diphenhydramine level and sedative and antihistamine effects

C. Hignite, D. Azarnoff, S. Carruthers, 1978 .

Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms.

D. Shen, D. Azarnoff, M. Fixley, 1978, Journal of pharmaceutical sciences.

A comparison of the number of circulating blood cells in different parts of the circulatory system.

D. Azarnoff, T. Batty, P. G. Roofe, 1951, Science.

Absorption of digoxin from different oral preparations in normal subjects during steady state

D. Azarnoff, D. Huffman, C. Manion, 1974, Clinical pharmacology and therapeutics.

Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline.

D. Shen, D. Azarnoff, M. Fixley, 1977, American Review of Respiratory Disease.

Placental transfer of diphenylhydantoin in the goat.

R. Kauffman, D. Azarnoff, B. Boulos, 1972, Biochemical pharmacology.

Species differences in the plasma protein binding of desipramine

D. Azarnoff, F. Sjöqvist, O. Borgå, 1968, The Journal of pharmacy and pharmacology.

Bioavailability studies on para-aminosalicylic acid and its various salts in man. I. Absorption from solution and suspension

D. Azarnoff, S. H. Wan, P. Pentikainen, 1974, Journal of Pharmacokinetics and Biopharmaceutics.

In defense of the Drug Research Board.

D. Azarnoff, 1975, Journal of the American Medical Association (JAMA).

Prescription writing by generic name and drug cost.

D. Azarnoff, D. Hunninghake, J. Wortman, 1966, Journal of chronic diseases.

Drugs and Drug Metabolites as Environmental Contaminants: Detection of Chlorophenoxyisobutyrate and Salicylic Acid by GC-MS

C. Hignite, D. Azarnoff, 1977 .

The clinical use of plasma drug concentrations.

R. Gugler, D. Azarnoff, 1976, Rational drug therapy.

662 – STRUCTURE-ACTIVITY RELATIONSHIPS OF CLOFIBRATE-LIKE COMPOUNDS ON LIPID METABOLISM

T. Fitzgerald, D. Azarnoff, J. Reddy, 1977 .

The interaction between halofenate and propranolol

D. Azarnoff, C. Dujovne, D. Shoeman, 1976, Clinical pharmacology and therapeutics.

Comparison of charcoal and attapulgite as gastrointestinal sequestrants in acute drug ingestions.

J. Atkinson, D. Azarnoff, 1971, Clinical toxicology.

Bioavailability of aminosalicylic acid and its various salts in humans IV: comparison of four brands of the sodium salt.

P. Pentikäinen, D. Azarnoff, S. H. Wan, 1974, Journal of pharmaceutical sciences.

Effect of colestipol on gastrointestinal absorption of chlorothiazide in man

R. Kauffman, D. Azarnoff, Daniel L. Azarnoff, 1973, Clinical pharmacology and therapeutics.

Pamatolol: Phase I evaluation of the pharmacodynamics of a cardioselective beta adrenoceptor blocking drug

D. Azarnoff, S. Carruthers, P. Pentikainen, 1978, Clinical pharmacology and therapeutics.

Tumors potentiating catecholamine-induced hypertension.

D. Azarnoff, C. Dujovne, B. Boulos, 1971, Life sciences. Pt. 1: Physiology and pharmacology.

The value of plasma-digoxin assay.

D. Azarnoff, D. Huffman, 1972, Lancet.

Application of blood level data to dinical trials

D. Azarnoff, 1974, Clinical pharmacology and therapeutics.

Omeprazole Can Prevent the Gastroduodenal Mucosal Injury Associated with Combined Use of Clopidogrel and Aspirin: 123

P. Lapuerta, M. Goldsmith, D. Azarnoff, 2008 .

MICROBODIES IN EXPERIMENTALLY ALTERED CELLS

D. Azarnoff, D. Svoboda, H. Grady, 1967, The Journal of cell biology.

Evidence That Inhibition of Hepatic Drug Oxidation by Tumors is Mediated by a Circulating Humor 1

D. Azarnoff, B. Boulos, D. Shoeman, 1972, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Effect of certain transition elements on cholesterol biosynthesis.

D. Azarnoff, G. L. Curran, 1961, Federation proceedings.

RESPONSE OF HEPATIC MICROBODIES TO A HYPOLIPIDEMIC AGENT, ETHYL CHLOROPHENOXYISOBUTYRATE (CPIB)

D. Azarnoff, D. Svoboda, 1966, The Journal of cell biology.

Assessment of the Safety and Efficacy Data for the Hypnotic Halcion(R): Results of an Analysis by an Institute of Medicine Committee

Robert D. Gibbons, Andrew M. Pope, David J. Kupfer, 1999 .

The Effects of Urine pH and Plasma Protein Binding on the Renal Clearance of Disopyramide

D. Shen, D. Azarnoff, J. Cunningham, 1977, Clinical pharmacokinetics.

Glutethimide and 4‐0H glutethimide: Pharmacokinetics and effect on performance in man

F. Bochner, D. Azarnoff, J. Crow, 1977, Clinical pharmacology and therapeutics.

Disposition kinetics of disopyramide in patients with renal insufficiency

D. Shen, D. Azarnoff, J. Cunningham, 1980, Biopharmaceutics & drug disposition.